Matching articles for "vimseltinib"
Vimseltinib (Romvimza) for Tenosynovial Giant Cell Tumor (online only)
The Medical Letter on Drugs and Therapeutics • April 14, 2025; (Issue 1726)
Vimseltinib (Romvimza – Deciphera), an oral kinase
inhibitor, has been approved by the FDA for treatment
of symptomatic tenosynovial giant cell tumor in adults
for whom surgical resection would cause...
Vimseltinib (Romvimza – Deciphera), an oral kinase
inhibitor, has been approved by the FDA for treatment
of symptomatic tenosynovial giant cell tumor in adults
for whom surgical resection would cause worsening
functional limitation or severe morbidity. The kinase
inhibitor pexidartinib (Turalio) was approved for a
similar indication in 2019.